COMPUMEDICS WINS MAJOR NEUROLOGICAL MONITORING CONTRACT WITH LEADING EUROPEAN EPILEPSY CENTER
- Significant A$1.0m (EUR0.6m) contract to supply Compumedics’ world leading neurological monitoring platform to Bethel Epilepsy Centre (Bethel) in Bielefeld-Bethel, Germany
- Bethel is one of Europe’s leading centres for the treatment and rehabilitation of people suffering from epilepsy
- Contract represents further validation of Compumedics’ neurological monitoring product offering
- Growing its neurological monitoring business in key international markets remains one of Compumedics’ core business growth objectives
Compumedics Limited (ASX: CMP) (“Compumedics” or “Company”) is pleased to announce it has signed a major contract to supply its world leading neurological monitoring systems (including the new generation Grael product platform) to Bethel Epilepsy Center, one of Europe’s leading centres for the treatment of epilepsy.
Under the A$1.0m (approx. EUR0.6m) contract, Compumedics will ship systems in several stages over FY18 and FY19.
The Bethel Epilepsy Centre in Bielefeld-Bethel, the first German rehabilitation clinic for epilepsy patients, is one of Europe’s leading centres for treating and rehabilitating people with epilepsy. It has highly specialized diagnostic and treatment protocols, which include epilepsy surgery. Bethel is highly recognised for its research into better patient outcomes.
Mara, the hospital at Bethel, is the largest epilepsy hospital in Germany. It has 130 beds plus 35 places for rehabilitation in-patient treatment. In 2016, 2811 in-patients were treated. More than 100 epilepsy surgeries were performed, 17 of them after intracranial studies.
Professor Dr Bien, Bethel’s Clinical Director, said the primary reasons for purchasing Compumedics’ systems over four other internationally recognised vendors were the transparency and flexibility of Compumedics’ systems, particularly the ability to record, distribute and store high quality video and EEG signals. Also important were the knowledge and responsiveness of Compumedics staff, as well as the Company’s on-going commitment to working with key customers on innovative new solutions to improve patient outcomes and efficiencies within the clinical centre.
The Epilepsy Centre at Krankenhaus Mara, Bielefeld-Bethel, Germany
Dr. David Burton, Executive Chairman of Compumedics, said, “We are very pleased to announce this significant contract in Europe for Compumedics current generation of neurological monitoring technology, including the current and recently expanded Grael product platform.
“Compumedics was able to achieve this win against robust local and international competition in Germany, so this is a significant reference site for the Company in the critical German and wider European market. Compumedics will look to continue to expand its sleep and neurological diagnostic and monitoring businesses there.
“We are delighted that one of the key reasons Bethel purchased Compumedics neurological monitoring technology was because of our on-going commitment to seek new and innovative solutions that solve our customers problems and drive efficiencies in their practices, concurrent with better patient outcomes.”
About Compumedics Limited
Compumedics Limited [ASX: CMP] is a medical device company involved in the development, manufacture and commercialisation of diagnostics technology for the sleep, brain and ultrasonic blood-flow monitoring applications. The Company owns US based Neuroscan and Germany based DWL Elektronishe GmbH. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe and the Middle East.
Executive Chairman Dr. David Burton founded Compumedics in 1987. In the same year the Company successfully designed and installed the first Australian, fully computerised sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on the development of products that sold into the growing international sleep clinic and home monitoring markets.
Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia’s Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian governments.
For further information please contact:
Dr David Burton
Executive Chairman, CEO Executive Director
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399
Chief Financial Officer
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399
Investor Relations, Media & PR enquires:
Bourse Communications Pty Ltd
Phone: +61 3 9510 8309
Mobile: +61 408 670 706
Oxygen Financial PR
Ph: + 61 3 9915 6341
Mob: +61 403 493 049